On August 13, the Ministry of Food and Drug Safety announced that it has approved the rare disease drug 'Vonjo Capsule (pacritinib citrate)' for the treatment of myelofibrosis.


MFDS Approves Rare Disease Drug 'Vonjo Capsule' for Myelofibrosis Treatment View original image

Myelofibrosis is a type of myeloproliferative neoplasm, characterized by the fibrosis of bone marrow tissue responsible for hematopoiesis, resulting in the impairment of normal blood cell production.


Vonjo Capsule is used to treat adult patients with primary or secondary myelofibrosis, including cases that develop following polycythemia vera or essential thrombocythemia. With this approval, it is expected to provide a new treatment opportunity for severe patients—specifically those in the intermediate to high-risk categories who cannot use existing therapies due to platelet counts below 50×109/L.


The Ministry explained that the drug was designated as the 32nd product under the 'Global Innovative Product Fast-Track Review System (GIFT)' and underwent expedited review to ensure rapid introduction into clinical practice.



A representative from the Ministry of Food and Drug Safety said, "We will continue to do our utmost to expand patient access to treatments by swiftly reviewing and approving therapies that have been thoroughly verified for safety and efficacy, based on our expertise in regulatory science."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing